GHP Q3 2021

GHP / Q3 2021 33 , CanaQuest Medical Corp has found its place in the world as a leader in the field of life science and pharmaceuticals. The teamhas developed twomaster formulations which could have an incredible impact on the pharmaceutical sector at large. Worthy winners in GHP’s rolling series of Global Excellence Awards, where the firmwas named Best Medical Cannabis and Botanical Oils Product Development Company, 2021 - North America, we thought it time to dig a little deeper into the secrets of their success. What does it mean to work in the rapidly expanding CBD field? For the team at CanaQuest, it means exploring new and exciting possibilities for development. There are now many companies proud to claim that their products have amazing benefits for many ailments, but few have conducted detailed scientific research and have the evidence to back up their claims. CanaQuest places a great deal of pride in its results, with the team’s products carefully developed through pre-clinical trials in conjunction with Dr. Steven Laviolette and his 13-member team at Western University. This academic background has been key to the team’s continued success, and the development of their two products Mentanine® and Mentabinol®. These products are specifically designed to treat multiple mental health ailments such as anxiety, depression, PTSD, schizophrenia, pain management and addiction. Mentanine® combines CBD isolate and Omega-3 compounds to produce a product with over ten times the efficacy for the treatment of anxiety, depression, and PTSD when compared to pure CBD. The evidence from scientific trials shows that it Quest for Excellence also has a significant effect on inflammation, which could be beneficial to those who suffer from pain. Because of the carefully calculated formula, Mentanine® requires lower doses of CBD which reduces the negative side-effects of high CBD consumption. Mentabinol®, on the other hand, acts as the only safer alternative medication to any THC product on the market. Unlike these products, it does not produce negative psychiatric sideeffects. The team’s preclinical trials demonstrate a clear reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity and gene vulnerability. The benefits of working with Dr. Laviolette’s pre-clinical trial results are obvious, and have allowed the team a pathway to the initiation of human trials with select Universities. Thanks to this incredibly forwardthinking approach, CanaQuest is well on the way to becoming a global leader in the formulation and development of health products from cannabinoids and botanical derivatives. Unlike the competition, the focus on the serious scientific benefits of what they produce are certain to be the key behind the firm’s success in the broader market. The impact of COVID-19 on every industry has been immense, but for CanaQuest it has brought about both benefits and challenges. On the one hand, it has prevented the team from visiting the various facilities with which it has partnered, delaying rollout significantly. That said, the pandemic has allowed the team to explore other options with their products and it seems that Mentanine® could be an effective treatment for LongHaulers Syndrome aftereffects. This path is currently being investigated by the team. Needless to say, both Mentanine® and Mentabinol® are well on their way to market, allowing the company to reinvest in clinical trials and the development of new Rx medical formulations. The development in the CBD field has been astonishing, but few have taken the care and provided the same depth of attention to detail as the team at CanaQuest. We celebrate their amazing achievement in the industry and look forward to seeing them grow rapidly as their products come to the attention of the general public. Company: CanaQuest Medical Corp Name: Paul Ramsay Email: [email protected] Web Address: